NCT07433465

Brief Summary

This prospective study evaluates a target population of pregnant women at the time of pregnancy diagnosis to investigate the predictive value of serum ferritin (SF) levels for the later development of gestational diabetes mellitus (GDM). The intervention involves measuring early-pregnancy SF, transferrin, and hemoglobin levels, alongside HbA1c, and comparing these biomarkers between women who later develop GDM and those who remain normoglycemic. The primary outcome is to assess the success rate of this diagnostic regimen in identifying high-risk individuals, aiming to establish SF as a valuable early biomarker for GDM to enable timely interventions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
556

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 5, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 7, 2024

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 20, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 25, 2026

Completed
Last Updated

February 25, 2026

Status Verified

February 1, 2026

Enrollment Period

2 years

First QC Date

February 20, 2026

Last Update Submit

February 20, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Success Rate of Diagnostic Regimens in Predicting Gestational Diabetes Mellitus

    The efficacy of early pregnancy Serum Ferritin (SF) levels in accurately identifying women who will subsequently meet the diagnostic criteria for GDM.

    24-28 weeks gestation

Secondary Outcomes (1)

  • Iron Homeostasis Markers

    24-28 weeks gestation

Study Arms (2)

GDM Group

Pregnant women who develop gestational diabetes mellitus later in pregnancy.

Diagnostic Test: Glycemic Markers

Non GDM Group

Pregnant women who maintain normal glucose tolerance throughout pregnancy.

Diagnostic Test: Glycemic Markers

Interventions

Glycemic MarkersDIAGNOSTIC_TEST

Fasting blood glucose (FBG), 2-h Post postprandial blood glucose (PPBG), HbA1c, and Fasting Serum Insulin (FSI).

GDM GroupNon GDM Group

Eligibility Criteria

Age21 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant women at the time of their initial pregnancy diagnosis, typically presenting at prenatal or outpatient clinics.

You may qualify if:

  • Confirmed pregnancy at an early gestational age.
  • Provision of clinical and family history (e.g., age, BMI, history of GDM).

You may not qualify if:

  • Pre-existing Type 1 or Type 2 Diabetes Mellitus.
  • Conditions known to significantly alter iron metabolism independent of pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha University

Banhā, Al Qalyoubia, 13511, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Venous blood samples were drawn aseptically from the antecubital vein for molecular and biochemical analysis. Sample Types \& Collection: Fluoride-containing tubes: Used for blood samples intended for Fasting Blood Glucose (FBG) and 2-hour postprandial blood glucose (PPBG) estimation. EDTA-containing tubes: Used for blood samples intended for HbA1c estimation. Serum Processing: Blood was collected in clean tubes, allowed to clot, and centrifuged at 1000 rpm for 10 minutes to separate the serum. Storage Conditions: Serum Storage: Samples were kept frozen at -20 °C for the later estimation of insulin, ferritin, iron, and Total Iron-Binding Capacity (TIBC) via ELISA. Laboratory Parameters Measured: Glycemic Markers: FBG, 2-h PPBG, HbA1c, and Fasting Serum Insulin (FSI). Iron Indices: Serum ferritin, serum iron, TIBC, transferrin saturation (TF), and hemoglobin concentration

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Obestitrics and gynecology

Study Record Dates

First Submitted

February 20, 2026

First Posted

February 25, 2026

Study Start

December 5, 2022

Primary Completion

December 7, 2024

Study Completion

October 10, 2025

Last Updated

February 25, 2026

Record last verified: 2026-02

Locations